XCUR XCUR
Company Profile ↓Company Overview
XCUR (XCUR) is a publicly traded company listed on with a market capitalization of $8.35M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -68.43% |
| 6 Months: | -71.41% |
| 3 Months: | -53.05% |
| 1 Month: | +4.80% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.78 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 82.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Mar 2017 | May 2017 | Jun 2017 | Aug 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 2.69M | - | 2.50M | - | 36.00K | 19.00K | 57.00K | 6.00K | 25.00K | 434.00K | 527.00K | 310.00K | 9.18M | 4.85M | 2.44M | 140.00K | 997.00K | 79.00K | - | - | - | - | 0 | 0 | 0 | 500.00K | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.02M | 2.45M | 2.39M | 2.26M | 1.60M |
| Operating Income | -3.26M | -2.48M | -17.83K | -2.72M | -11.90K | -1.89M | - | -5.28M | -5.80M | -5.86M | - | -5.58M | -4.98M | -5.95M | - | 534.00K | -4.39M | -9.12M | - | -12.16M | -13.86M | -23.08M | -7.74M | -7.48M | -5.21M | -4.54M | -5.64M | -3.32M | -836.00K | -1.24M | -2.57M | - | -3.02M | -2.45M | -2.39M | -2.26M | -1.60M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.92M | -2.32M | -2.37M | -3.37M | -1.50M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | 0 | 1.00K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.01M | -2.62M | -2.44M | -3.53M | -1.83M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | -634.00K | 0 |
| Net Income | -3.53M | -2.65M | -18.05K | -2.98M | -12.28K | -1.93M | -3.44M | -5.51M | -6.83M | -5.32M | -4.75M | -5.29M | -5.22M | -5.82M | -9.98M | 1.15M | -4.31M | -8.82M | -12.69M | -12.48M | -14.27M | -23.53M | -8.35M | -7.47M | -5.16M | -4.41M | -5.76M | -5.26M | -829.00K | -600.00K | -1.09M | - | 3.01M | -2.62M | -2.44M | -2.90M | -1.83M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -0.12 | - | - | - | 0.01 | -0.05 | -0.10 | -0.15 | -0.14 | -4.86 | -8.01 | -2.07 | -1.66 | -1.04 | -0.70 | -0.68 | -3.04 | -0.48 | -0.35 | -0.57 | - | 0.49 | -0.41 | -0.39 | - | -0.29 |
| R&D Expense | 2.41M | 3.49M | - | 3.30M | - | 3.12M | - | 3.27M | 3.83M | 4.00M | - | 3.40M | 3.43M | 4.25M | - | 6.08M | 7.01M | 9.14M | - | 10.26M | 10.84M | 16.46M | 7.14M | 6.75M | 4.80M | 1.42M | 0 | 0 | 0 | 0 | 0 | - | 808.00K | 935.00K | 888.00K | - | 312.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.04M | 9.72M | 118.00K | 1.30M | 16.61M | -483.00K | 28.83M | 0 | 500.00K | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 30.66M | 13.14M | 5.45M | 10.12M |
| Operating Income | -16.16M | -10.41M | -21.82M | -26.62M | -25.44M | -62.55M | -1.83M | -13.14M | -4.95M | -10.12M |
| EBITDA | - | - | - | - | - | - | 78.00K | -15.54M | -8.85M | -5.12M |
| Interest Expense | - | - | - | - | - | - | 595.00K | 0 | 18.00K | 1.00K |
| Pretax Income | - | - | - | - | - | - | -2.37M | -16.91M | -9.69M | -5.58M |
| Tax Provision | - | - | - | - | - | - | 209.00K | 0 | 8.00K | -634.00K |
| Net Income | -16.94M | -11.01M | -22.41M | -26.30M | -24.67M | -64.10M | -2.58M | -16.91M | -9.70M | -4.95M |
| Diluted EPS | - | - | - | - | -0.28 | -21.70 | -2.80 | -10.55 | -4.75 | -0.79 |
| R&D Expense | 13.66M | 13.08M | 14.12M | 19.34M | 32.09M | 48.98M | 19.77M | 1.42M | 0 | 3.29M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 20.58M | 28.99M | 28.76M | 115.26M | 100.44M | - | 23.33M | 11.58M | 15.06M | 14.04M |
| Current Assets | - | - | - | - | - | - | - | 10.05M | 2.02M | 13.67M | 4.62M |
| Cash & Equivalents | 18.73M | 19.62M | 25.76M | 26.27M | 48.46M | 33.26M | - | 8.58M | 816.00K | 12.51M | 3.75M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 0 | - | - | - | - |
| Total Liabilities | - | 18.13M | 9.01M | 7.80M | 34.52M | 38.94M | - | 8.41M | 8.55M | 8.28M | 10.12M |
| Current Liabilities | - | 12.16M | 3.36M | 2.04M | 31.09M | 13.73M | - | 1.64M | 2.51M | 3.07M | 3.89M |
| Long Term Debt | - | 4.45M | 4.86M | 4.92M | 0 | 16.59M | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | 7.31M | 6.67M | 5.93M | 176.00K |
| Total Equity | 18.23M | 2.45M | 19.98M | 20.95M | 80.75M | 61.51M | - | 14.92M | 3.03M | 6.77M | 3.93M |
| Shares Outstanding | - | - | - | - | - | - | - | 993.18K | 1.73M | 6.03M | 6.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.05M | -19.79M | -19.49M | 1.32M | -39.27M | - | -35.66M | -10.36M | -2.91M | -8.55M |
| Investing Cash Flow | -394.00K | -926.00K | -94.00K | -63.43M | 10.14M | - | 4.70M | -1.08M | 0 | -1.81M |
| Financing Cash Flow | 6.34M | 26.86M | 20.09M | 84.31M | 15.13M | - | -3.10M | 3.67M | 13.40M | 1.60M |
| Capital Expenditure | -394.00K | -926.00K | -94.00K | -1.08M | -3.17M | -968.00K | -10.00K | - | - | -1.00K |
| Free Cash Flow | -5.44M | -20.71M | -19.58M | 235.00K | -42.44M | - | -35.67M | -10.36M | -2.91M | -8.56M |
| Net Change in Cash | - | - | - | - | - | - | -34.07M | -7.76M | 10.49M | -8.76M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -1,560.0% | -107.1% | -18,490.7% | -2,053.8% | -153.1% | 12,950.1% | -6.4% | - | -989.8% | - |
| Net Margin % | -1,635.2% | -113.3% | -18,994.1% | -2,029.6% | -148.5% | 13,271.6% | -9.0% | - | -1,940.2% | - |
| ROE % | -692.0% | -55.1% | -107.0% | -32.6% | -40.1% | - | -17.3% | -558.0% | -143.3% | -126.0% |
| ROCE % | -192.0% | -40.6% | -81.7% | -31.6% | -29.3% | - | -8.4% | -144.9% | -41.3% | -99.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 0.66% | 43.11K | $55.61K |
| 2 | Geode Capital Management, LLC | 0.48% | 31.25K | $40.31K |
| 3 | Jane Street Group, LLC | 0.45% | 29.54K | $38.10K |
| 4 | Citadel Advisors Llc | 0.23% | 14.92K | $19.25K |
| 5 | Vanguard Fiduciary Trust Co | 0.20% | 13.16K | $16.98K |
| 6 | Northwestern University | 0.16% | 10.43K | $13.45K |
| 7 | Tower Research Capital LLC (TRC) | 0.06% | 4.07K | $5.25K |
| 8 | UBS Group AG | 0.01% | 342 | $441 |
| 9 | Morgan Stanley | - | 143 | $184 |
| 10 | Royal Bank of Canada | - | 82 | $105 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XCUR
Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement
WILMINGTON, Del., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that, on September 10, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock …
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) durin…
Exicure Announces Board and Committee Changes
WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced changes to its Board of Directors and Board committees following actions approved by the Company's Board of Direct…
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on …
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) …
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combinat…
XCUR — Frequently Asked Questions
What is the current share price of XCUR?
As of 2026-09-16 18:39 PDT, XCUR trades at $1.31 on NASDAQ/NYSE. Its 52-week range is $1.15 to $7.29.
What is the market capitalisation of XCUR?
XCUR has a market capitalisation of $8.35M on NASDAQ/NYSE.
What is the P/E ratio of XCUR?
XCUR trades at a trailing price-to-earnings (P/E) ratio of -1.66. Its price-to-book (P/B) ratio is 2.18.
What is the return on equity (ROE) of XCUR?
XCUR has a return on equity (ROE) of -125.98%. Its return on capital employed (ROCE) is -99.65%.
Is XCUR a good stock to buy?
This page provides a data-driven analysis of XCUR, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.